Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Telix Pharmaceuticals Ltd. ( (AU:TLX) ) has issued an announcement.
Telix Pharmaceuticals has completed the acquisition of assets from ImaginAb, Inc., including a pipeline of next-generation therapeutic candidates and a novel biologics technology platform. This acquisition is expected to enhance Telix’s innovation capabilities and expand its therapeutics pipeline, targeting validated and novel cancer targets. With the integration of a Los Angeles research facility and ImaginAb’s team, Telix aims to advance its position in precision medicine and theranostic radiopharmaceuticals, potentially impacting its operations, industry standing, and stakeholder interests.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, Canada, Europe, and Japan. The company develops a portfolio of clinical and commercial stage products targeting unmet medical needs in oncology and rare diseases.
YTD Price Performance: 27.45%
Average Trading Volume: 4,346
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $5.91B
Learn more about TLX stock on TipRanks’ Stock Analysis page.
